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ABSTRACT
Amongst the regulators of voltage-gated ion channels is the collapsin response mediator protein
2 (CRMP2). CRMP2 regulation of the activity and trafficking of NaV1.7 voltage-gated sodium
channels as well as the N-type (CaV2.2) voltage-gated calcium channel (VGCC) has been reported.
On the other hand, CRMP2 does not appear to regulate L- (CaV1.x), P/Q- (CaV2.1), and R- (CaV2.3)
type high VGCCs. Whether CRMP2 regulates low VGCCs remains an open question. Here, we asked
if CRMP2 could regulate the low voltage-gated (T-type/CaV3.x) channels in sensory neurons.
Reducing CRMP2 protein levels with short interfering RNAs yielded no change in macroscopic
currents carried by T-type channels. No change in biophysical properties of the T-type currents
was noted. Future studies pursuing CRMP2 druggability in neuropathic pain will benefit from the
findings that CRMP2 regulates only the N-type (CaV2.2) calcium channels.
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Regulators of voltage-gated calcium channels
(VGCCs) shape a diversity of biological functions
within the nervous system 1,2. In chronic pain,
proteins regulating the N-type (CaV2.2) VGCCs
can modulate nociception [1]. One such protein is
the collapsin response mediator protein 2 (CRMP2)
[3–15]. Our continuing studies have established
CRMP2 as a bona fide binding partner and regu-
lator of the presynaptic trafficking of CaV2.2
[4,8,13,15–18]. In neuropathic pain, increased phos-
phorylation of CRMP2 by cyclin-dependent kinase
5 defines the presynaptic content for CaV2.2, but
not for CaV2.3 (i.e. the R-type) VGCCs [3,13,19].
In a proteomic study, the L-type VGCC was shown
to be part of the CRMP2 interactome [20] likely
though a motif in the C-terminus in the CaV1.2 L-
type channel [21]. While CRMP2-dependent regu-
lation of CaV2.1 (i.e. the P/Q-type) VGCC has
never been investigated, CRMP2 interaction
domains found in CaV2.2 are poorly conserved in
CaV2.1 or other channels [21]. In investigating
CRMP2 phosphorylation with the small molecule
(S)-lacosamide, we found that only calcium influx
via N-type, but not other high-voltage gated chan-
nels, was blocked [5]. Collectively, these results
hinted at a specific action of CRMP2 on N-type
VGCCs.
Loss of CRMP2 expression abolishes patholo-
gical pain [11,19]. This reversal of pain was
attributed to decreased excitability of dorsal
root ganglion (DRG) neurons likely due to
CRMP2-dependent effects on the trafficking
and activity of the NaV1.7 voltage-gated sodium
channel [22]. Further work from our group
revealed that a peptide derived from the
CRMP2/CaV2.2 interface (designated CBD3, for
calcium binding domain 3) decreased the fre-
quency of spontaneous excitatory postsynaptic
potentials in spinal cord [18]. A single mutation
that stabilized CBD3’s helical structure rendered
the mutant peptide capable of inhibition of sen-
sory neuron excitability [23]. This suppression of
excitability was not related to inhibition of
sodium channels but rather linked to impair-
ment of T-type (CaV3.x) channel function [23].
T-type VGCCs are low voltage-activated calcium
channels important for the initiation of an
action potential [1,24,25]. In neuropathic pain,
CaV3.2 channels were reported to be increased
at presynaptic sites through a trafficking
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mechanism [26]. Thus, the observations that (1)
a peptide derived from CRMP2 could inhibit T-
type VGCCs [23] and (2) T-type VGCCs are
increased in a model where CRMP2 is dysregu-
lated, together support the hypothesis that
CRMP2 could modulate T-type VGCCs.
To directly test whether CRMP2 could regulate T-
type calcium currents in DRG sensory neurons, we
used a previously validated short interfering RNA
(siRNA) against CRMP2 [19,27] to knockdown
CRMP2 protein levels. Rat DRG neurons were co-
transfected with CRMP2 siRNA or control siRNA
and (~50 ng) of green fluorescent protein (GFP)
expressing plasmid to identify the transfected cells
prior to electrophysiological recordings. We used
electrophysiology protocols described before [24] to
record T-type currents. From a holding potential of
−90 mV, we used 200-ms depolarization steps to
change the membrane potential from −70 to
+60 mV (10 mV increments) to evoke prototypical
T-type calcium currents (Figure 1(a)). After transfec-
tion with CRMP2 (n = 15) or control (n = 17) siRNA,
we recorded low voltage-activated calcium currents
(Figure 1(a)) from DRG neurons with an average
diameter between 20 and 30 µm. We measured cur-
rent–voltage (I–V) relationships (Figure 1(b)) and
observed that loss of CRMP2 expression had no effect
on T-type calcium current amplitudes at all test
potentials tested (Figure 1(b)). At peak current density
(−10 mV), no difference was found between CRMP2
siRNA or control siRNA transfected DRG neurons
(Figure 1(c) and Table 1). Knockdown of CRMP2 did
not alter the channel gating properties as wemeasured
a similar half-maximal activation (V0.5) of T-type
calcium channels in both transfected conditions
(Figure 1(d)). The kinetics of macroscopic current
inactivation (Figure 1(e)) were unchanged at all mem-
brane potentials tested (−40 mV, Figure 1(f)). The
time-dependent activation (10–90% rise time) of T-
type currents was not affected by loss of CRMP2
expression (Figure 1(g–h)). We next tested whether
CRMP2 could control the voltage-dependent kinetics
of channel inactivation (Figure 1(i)) and found this
property to also not be affected by CRMP2 siRNA
transfection. Deactivating tail currents calculated
using the single exponential function: y = A1 × e(−x/
τ1) + y0, where A1 is the amplitude, τ1 is the decay
constant, and y0 is the offset. The resulting τ values
(Figure 1(j)), showed no differences irrespective of
CRMP2 expression. Finally, because upon long mem-
brane hyperpolarizations in DRG neurons T-type
calcium channels can recover from inactivation, we
tested if this biophysical parameter could be contin-
gent on CRMP2. This property has important con-
sequences on the firing properties of sensory neurons
expressing T-type calcium channels. Thus, we tested
the recovery from inactivation using a double-pulse
protocol with a variable interpulse duration at
−90mV (Figure 1(k)) after a 500-ms-long inactivating
pulse (Vh = −90 mV; Vt = −30 mV). T-type currents
recovered fully, independently of the transfection con-
dition (Figure 1(k)). Taken together, our results show
that CRMP2 has no role to play on regulation of T-
type calcium currents and gating properties of these
T-type calcium channels. We previously reported that
CRMP2 has no effect on the R-type VGCC [13]. The
present results showing the lack of CRMP2 regulation
of T-type VGCC suggest now to support the assertion
that CRMP2 is a specific regulatory protein for
CaV2.2 but for no other type of VGCCs. This speci-
ficity is an important step in furthering our under-
standing of the contribution of CRMP2 in
neuropathic pain.
We conclude that CRMP2 regulation of NaV1.7
[9,10,12,13,22,28] is responsible for controlling
DRG neurons excitability and that CRMP2 regula-
tion of CaV2.2 is responsible for increased neuro-
transmitter release at the primary afferent
[11,13,17,18]. For future therapeutic targeting, the
specificity of action of CRMP2 toward CaV2.2 will
reduce the potential for unwanted effects of novel
CRMP2-targeted compounds.
Methods
Preparation of rat DRG cultures (acutely
dissociated neurons)
DRG neurons were cultured using methods as
described previously [29]. Collected dorsal root
ganglia were digested in an enzymatic combination
containing bicarbonate-free, serum-free, sterile
DMEM (Cat# 11965, Thermo Fisher Scientific) solu-
tion, neutral protease (3.125 mg/mL, Cat#LS02104;
Worthington, Lakewood, NJ), and collagenase type I
(5 mg/mL, Cat# LS004194,Worthington, Lakewood,
NJ). After incubation for approximately 1 h with
gentle agitation under 37°C, DRG neurons were
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centrifuged post-dissociation and isolated from
DRGmedia (DMEM containing 1% penicillin/strep-
tomycin sulfate from 10,000 μg/mL stock, 30 ng/mL
nerve growth factor, and 10% fetal bovine serum
[Hyclone]). Dissociated DRG neurons were subse-
quently plated onto 12- mm laminin and poly-D-
lysine-coated coverslips. Cultures were utilized
before 2-days’ time.
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Figure 1. CRMP2 does not affect T-type Ca2+ currents in dorsal root ganglion (DRG) sensory neurons. (a) Representative family of
traces of T-type Ca2+ currents fromDRG sensory transfectedwith either control or CRMP2 siRNA. Voltage protocol used to evoke the currents is
shown. Summary of the normalized (pA/pF) T-type calcium current density versus voltage relationship (b) andpeak T-type Ca2+ current density
at−10mV (mean± SEM) (c) fromDRG sensory neurons transfected as indicated. (d) Boltzmann fits for normalized conductanceG/Gmax voltage
relations for voltage-dependent activation of T-type currents. (e) Inactivation τ (single-exponential fit of decaying portion of the current
waveforms using a single-exponential equation: y= A1 × e(−x/τ1) + y0, where A1 is the amplitude, τ1 is the decay constant, and y0 is the offset),
isolated at −40 mV (f) and (g) time-dependent activation (10–90% rise time) from I–V curves and at −40 mV (h) in DRG cells shown in (b).
Boltzmann fits for normalized conductance G/Gmax voltage relations for voltage-dependent inactivation (i) of sensory neurons treated as
indicated. (j) Deactivating tail currents in DRGneurons transfectedwith control or CRMP2 siRNAwere fit with a single-exponential function. The
resulting τ values are plotted. (k) Recovery from inactivation in indicated groups. Data are averaged and fitted by double exponential
association (P > 0.05, n > 12 per condition). All graphs show mean ± SEM with individual data points showed when possible.
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Transfection of rat primary DRG neurons
Collected cells were resuspended in nucleofector
transfection reagent containing 6 μL (50 nM)
scrambled or CRMP2 siRNA plus 6 µL GFP
(0.5 μg/μL). Then, cells were subjected to electro-
poration protocol O-003 in an Amaxa Biosystems
(Lonza) and plated onto 12- mm poly-D-lysine-
and laminin-coated glass coverslips.
Whole-cell electrophysiological recordings of
calcium currents in acutely dissociated DRG
neurons
The protocol for isolating T-type calcium cur-
rents was previously described by Choe et al.
[24]. The extracellular recording solution used
to isolate T currents consisted of the following
(in millimolar): 2CaCl2, 152 TEA-Cl, 10
HEPES, pH adjusted to 7.4 with TEA-OH.
The intracellular recording solution consisted
of (in millimolar) 135 tetramethylammonium
hydroxide, 10 EGTA, 40 HEPES, and 2
MgCl2, pH adjusted to 7.2 with hydrofluoric
acid. As previously described, the majority of
acutely dissociated small DRG cells express T
currents [24]. Thus, in order to record T-type
calcium currents, we focused on small DRG
neurons with an average soma diameter of
20–30 μm.
To avoid contamination by residual High
Voltage Activated (HVA) currents which are
present at more positive membrane potentials,
we measured the T-type Ca2+ current from the
peak, which was subtracted from the current at
the end of the depolarizing test potential.
Activation of ICa-T was measured by using a
holding voltage of −90 mV with voltage steps
200 ms in duration applied at 500-ms intervals
in 10 mV increments from −70 to +60 mV.
Inactivation of ICa-T was determined by apply-
ing an 1500-ms conditioning prepulse (−110 to
+20 mV in 10 mV increments) after which the
voltage was stepped to −30 mV for 20 ms; a
40-ms interval with a holding voltage of
−90 mV separated each acquisition. In the
deactivation tau protocol, the neuron was first
hold at −110 mV, then the voltage jumped to
−30 mV for 10 ms followed by a 50-ms con-
ditioning prepulse (−160 to −40 mV in 10 mV
increments). A 2-s interval with a holding vol-
tage of −90 mV separated each acquisition. ICa-
T recovery from inactivation was obtained by
using our standard double-pulse protocol with
variable interpulse duration at −90 mV after a
500-ms-long inactivating pulse (Vh = −90 mV;
Vt = −30 mV).
The Boltzmann relation was used to deter-
mine the voltage dependence for activation of
ICa wherein the conductance–voltage curve was
fit by the equation G/Gmax = 1/[1+ exp
(V0.5 − Vm)/k], where G is the conductance
G = I/(Vm − ECa), Gmax is the maximal con-
ductance obtained from the Boltzmann fit
under control conditions, V0.5 is the voltage
for half-maximal activation, Vm is the mem-
brane potential, and k is a slope factor. ECa is
the reversal potential for ICa. The values of ICa
around the reversal potential were fit with a
linear regression line to establish the voltage at
which the current was zero. The Boltzmann
parameters were determined for each indivi-
dual neuron and then used to calculate the
mean ± SEM.
Table 1. Gating properties of T-type calcium channels in DRG neurons.a
Control siRNA
Activation
V1/2 (P = 0.10) −22.7 ± 1.6(17) −26.3 ± 1.4(16)
k (P = 0.42) 12.8 ± 1.7(17) 11.0 ± 1.4(16)
Inactivation
V1/2 (P = 0.41) −54.9 ± 1.1(18) −53.6 ± 1.1(18)
k (P = 0.94) −9.4 ± 1.0(18) −9.5 ± 1.0(18)
Recovery
τ1 (ms) (P = 0.87) 1036.0 ± 217.2(15) 981.0 ± 255.1(18)
τ2 (ms) (P = 0.82) 25.2 ± 4.8(15) 27.2 ± 6.9(18)
aValues are means ± SEM calculated from fits of the data from the indicated number of individual cells (in parentheses) to the Boltzmann equation;
V1/2 midpoint potential (mV) for voltage-dependent activation or inactivation; k, slope factor. τ1 and τ2, time constants; the data could only be fit
with a double exponential equation as reported by the Todorovic group [24] and P > 0.05; Student’s t test.
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